AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.
Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly.
Eli Lilly Rises 1.5% After Key Trading Signal A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.
Top S&P500 movers in Friday's session Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.
